Subcutaneous (s.c.) administration of monoclonal antibodies (mAbs) can reduce treatment burden for patients and healthcare systems compared with intravenous (i.v.) infusion through shorter administration times, made possible by convenient, patient‐centric devices. A deeper understanding of clinical pharmacology principles related to efficacy and safety of s.c.‐administered mAbs over the past decade has streamlined s.c. product development. This review presents learnings from key constituents of the s.c. mAb development pathway, including pharmacology, administration variables, immunogenicity, and delivery devices. Restricted mAb transportation through the hypodermis explains their incomplete absorption at a relatively slow rate (pharmacokinetic (PK)) and may impact mAb‐cellular interactions and/or onset and magnitude of physiological responses (pharmacodynamic). Injection volumes, formulation, rate and site of injection, and needle attributes may affect PKs and the occurrence/severity of adverse events like injection‐site reactions or pain, with important consequences for treatment adherence. A review of immunogenicity data for numerous compounds reveals that incidence of anti‐drug antibodies (ADAs) is generally comparable across i.v. and s.c. routes, and complementary factors including response magnitude (ADA titer), persistence over time, and neutralizing antibody presence are needed to assess clinical impact. Finally, four case studies showcase how s.c. biologics have been clinically developed: (i) by implementation of i.v./s.c. bridging strategies to streamline PD‐1/PD‐L1 inhibitor development, (ii) through co‐development with i.v. presentations for anti‐severe acute respiratory syndrome‐coronavirus 2 antibodies to support rapid deployment of both formulations, (iii) as the lead route for bispecific T cell engagers (BTCEs) to mitigate BTCE‐mediated cytokine release syndrome, and (iv) for pediatric patients in the case of dupilumab.
Curcumin and its analogs exhibited antileukemic activity either as single agent or in combination therapy. Dimethoxycurcumin (DMC) is a more metabolically stable curcumin analog that was shown to induce the expression of promoter-methylated genes without reversing DNA methylation. Accordingly, co-treatment with DMC and DNA methyltransferase (DNMT) inhibitors could hypothetically enhance the re-expression of promoter-methylated tumor suppressor genes. In this study, we investigated the cytotoxic effects and epigenetic changes associated with the combination of DMC and the DNMT inhibitor decitabine (DAC) in primary leukemia samples and cell lines. The combination demonstrated antagonistic cytotoxic effects and was minimally cytotoxic to primary leukemia cells. The combination did not affect the metabolic stability of DMC. Although the combination enhanced the downregulation of nuclear DNMT proteins, the hypomethylating activity of the combination was not increased significantly compared to DAC alone. On the other hand, the combination significantly increased H3K27 acetylation (H3K27Ac) compared to the single agents near the promoter region of promoter-methylated genes. Furthermore, sequential chromatin immunoprecipitation (ChIP) and DNA pyrosequencing of the chromatin-enriched H3K27Ac did not show any significant decrease in DNA methylation compared to other regions. Consequently, the enhanced induction of promoter-methylated genes by the combination compared to DAC alone is mediated by a mechanism that involves increased histone acetylation and not through potentiation of the DNA hypomethylating activity of DAC. Collectively, our results provide the mechanistic basis for further characterization of this combination in leukemia animal models and early phase clinical trials.
Aim: There is a strong evidence that doxycycline can benefit abdominal aortic aneurysms patients because of its ability to inhibit matrix metalloproteinase enzymes. There is a need for a specific quantification method for doxycycline in these patients. We report herein the development and validation of a selective, specific, simple and rapid UHPLC–MS/MS method for doxycycline. Results: The assay was linear (r2 > 0.994) over a concentration range of 0.010–7.005 μg/ml. This validated method has good lower limit of quantification (LLOQ) (10 ng/ml), accuracies (89.1–103.4%), precision (≤7.0%) and extraction recoveries (95.8%). Doxycycline was stable during short- and long-term storage. Conclusion: The assay is reliable and has been successfully applied to serum samples obtained from the patients of N-TA3CT clinical study.
1 July 2020 in Journal of Advanced Pharmacy Research
Objectives: An ultra-performance liquid chromatography tandem mass spectrometry (UPLC–MS/MS) assay has been developed and validated for the quantification of oxycodone in rat serum and brain tissue homogenates. Methods: A simple extraction method using methyl-t-butyl ether was used for sample extraction with oxycodone–D3 as an internal standard (IS). A Symmetry® C18 column (100 mm x 4.6 mm, 5 µm) connected to a Phenomenex Luna® guard column (4 x 3 mm, 5 µm) was used for chromatographic separation. The mobile phase was composed of a mixture of acetonitrile and 0.1 % formic acid in water (pH = 2.7) (15:85, v/v). The flow rate was 0.4 mL/min, the total run time was 5 min, and the injection volume was 10 µL. The column and autosampler temperatures were maintained at 60 °C and 25 °C, respectively. Results: The calibration curve for oxycodone was linear over the range of 10–2000 ng/mL. Oxycodone extraction recovery from rat serum and brain samples ranged from 90.78–105.85 % and 98.42–104.38 % with relative standard deviation (RSD) values of 0.94–3.87 % and 1.04–2.82 %, respectively. The inter-day accuracy values ranged from 87.67–104.83 %, while the intra-day accuracy values ranged from 86.95–105.67 %. Conclusion: This method can be used for the quantification of oxycodone in samples obtained from preclinical animal studies and has great promise for applications in the quantification of oxycodone in human biological matrices.
1 July 2024 in Clinical Pharmacology & Therapeutics